Bionor is a biopharmaceutical company with first mover potential to advance a possible functional HIV cure

Latest news

Hide mandatory notifications of trade

Bionor Pharma – Preliminary result of the rights issue

Financial .2016

(Oslo, Norway, 30 September 2016) Reference is made to previous stock exchange announcements and the prospectus (the “Prospectus”) dated 14 September 2016 concerning the rights issue (the “Rights Issue”) of 525,000,000 new shares at a subscription price of NOK 0.10 per share in Bionor Pharma ASA (“Bionor” or the “Company”, ticker “BIONOR”).

Expiry of subscription period and last day of trading in subscription rights today

Financial .2016

(Oslo, Norway, 29 September 2016) Reference is made to previous stock exchange announcements and the prospectus (the “Prospectus”) dated 14 September 2016 concerning the rights issue (the “Rights Issue”) of 525,000,000 new shares at a subscription price of NOK 0.10 per share in Bionor Pharma ASA (“Bionor” or the “Company”, ticker “BIONOR”).

Expiry of subscription period and last day of trading in subscription rights tomorrow

Financial .2016

(Oslo, Norway, 28 September 2016) Reference is made to previous stock exchange announcements and the prospectus (the “Prospectus”) dated 14 September 2016 concerning the rights issue (the “Rights Issue”) of 525,000,000 new shares at a subscription price of NOK 0.10 per share in Bionor Pharma ASA (“Bionor” or the “Company”, ticker “BIONOR”).

Bionor Pharma – Preliminary result of the rights issue

Financial .2016

(Oslo, Norway, 30 September 2016) Reference is made to previous stock exchange announcements and the prospectus (the “Prospectus”) dated 14 September 2016 concerning the rights issue (the “Rights Issue”) of 525,000,000 new shares at a subscription price of NOK 0.10 per share in Bionor Pharma ASA (“Bionor” or the “Company”, ticker “BIONOR”).

Mandatory Notification of Trade - Additional information warrants

Financial .2016

(Oslo, Norway, 29 September 2016) Reference is made to the announcement on 14 September 2016 regarding the Rights Offering in Bionor Pharma ASA (the “Company”).

Mandatory Notification of Trade - Jens Krøis

Financial .2016

(Oslo, Norway, 29 September 2016) Reference is made to the announcement on 14 September 2016 regarding the Rights Offering in Bionor Pharma ASA (the “Company”).

Go to news section

Featured content